Abstract

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients
Anthony R Mato ...
Blood | VOL. 132
Anthony R Mato, et. al.Anthony R Mato ...
29 Nov 2018
Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)
Stephan Stilgenbauer ... Gilles Salles
Blood | VOL. 132
Stephan Stilgenbauer, et. al.Stephan Stilgenbauer ... Gilles Salles
29 Nov 2018
Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial
Valentin Goede ...
Blood | VOL. 134
Valentin Goede, et. al.Valentin Goede ...
13 Nov 2019
Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
Peter Hillmen ... Talha Munir
Blood | VOL. 132
Peter Hillmen, et. al.Peter Hillmen ... Talha Munir
29 Nov 2018
View more papers

More From: Blood

Paper Title
Journal
Date
Author
CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors.
Nayoung Kwon ... Diane S Krause
Blood | VOL. -
Nayoung Kwon, et. al.Nayoung Kwon ... Diane S Krause
05 Aug 2024
Asciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia – Results from the ASCEND Study
David T Yeung ... Timothy P Hughes
Blood | VOL. -
David T Yeung, et. al.David T Yeung ... Timothy P Hughes
05 Aug 2024
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
Esteban Arrieta-Bolaños ... Katharina Fleischhauer
Blood | VOL. -
Esteban Arrieta-Bolaños, et. al.Esteban Arrieta-Bolaños ... Katharina Fleischhauer
05 Aug 2024
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression
Belén Lopez-Millan ... Clara Bueno
Blood | VOL. -
Belén Lopez-Millan, et. al.Belén Lopez-Millan ... Clara Bueno
02 Aug 2024
View more papers